Most Read Articles
17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.
Pearl Toh, 24 Jul 2018
SGLT-2* inhibitors and GLP-1** agonists were associated with better survival compared with DPP-4*** inhibitors or control (placebo or no treatment) in patients with type 2 diabetes (T2D) who were inadequately controlled on metformin, according to a large network meta-analysis of 236 randomized trials.

Tenofovir better than entecavir in acute-on-chronic liver failure due to CHB reactivation

15 Mar 2019

A recent study has shown that the short-term efficacy of tenofovir disoproxil fumarate (TDF) is superior to entecavir (ETV) for the treatment of acute-on-chronic-liver failure (ACLF) due to reactivation of chronic hepatitis B (CHB).

Moreover, white blood cell count and hepatitis B virus (HBV)-DNA reduction at 2 weeks independently predict mortality at 3 months.

At 2 weeks, patients in the TDF vs ETV group had significantly higher HBV-DNA reduction (p=0.003), lower HBV-DNA level (p=0.001), higher rate of HBV-DNA undetectability (p=0.007), lower Child-Turcotte-Pugh (CTP; p=0.003) and model for end-stage liver disease scores (p=0.002).

At 3 months, all survivors had undetectable HBV-DNA, while CTP (p=0.970) and model for end-stage liver disease scores (p=0.192) were comparable between the two groups but markedly lower compared with baseline values (p<0.01). In addition, cumulative survival rate was significantly higher in the TDF vs ETV group (p=0.025).

White blood cell count (hazard ratio [HR], 2.726; 95 percent CI, 2.691–7.897; p=0.000) and HBV-DNA reduction (HR, 0.266; 0.033–0.629; p=0.013) at 2 weeks independently predicted mortality. The two study drugs were well tolerated.

In this study, a total of 67 consecutive patients with HBV-ACLF were assigned to groups receiving daily TDF (300 mg/d; n=32) or daily ETV (0.5 mg/d; n=35). Researchers prospectively followed these patients. Overall survival at 3 months was the primary endpoint.

“ACLF can be triggered by reactivation of CHB. TDF and ETV are now the most potent antiviral agents for CHB,” according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.
Pearl Toh, 24 Jul 2018
SGLT-2* inhibitors and GLP-1** agonists were associated with better survival compared with DPP-4*** inhibitors or control (placebo or no treatment) in patients with type 2 diabetes (T2D) who were inadequately controlled on metformin, according to a large network meta-analysis of 236 randomized trials.